Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

116 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Extracellular adenosine triphosphate and adenosine in cancer.
Stagg J, Smyth MJ. Stagg J, et al. Oncogene. 2010 Sep 30;29(39):5346-58. doi: 10.1038/onc.2010.292. Epub 2010 Jul 26. Oncogene. 2010. PMID: 20661219 Review.
Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment Approach.
Bareche Y, Buisseret L, Gruosso T, Girard E, Venet D, Dupont F, Desmedt C, Larsimont D, Park M, Rothé F, Stagg J, Sotiriou C. Bareche Y, et al. Among authors: stagg j. J Natl Cancer Inst. 2020 Jul 1;112(7):708-719. doi: 10.1093/jnci/djz208. J Natl Cancer Inst. 2020. PMID: 31665482 Free PMC article.
Immune regulation by mesenchymal stem cells: two sides to the coin.
Stagg J. Stagg J. Tissue Antigens. 2007 Jan;69(1):1-9. doi: 10.1111/j.1399-0039.2006.00739.x. Tissue Antigens. 2007. PMID: 17212702 Review.
NK cell-based cancer immunotherapy.
Stagg J, Smyth MJ. Stagg J, et al. Drug News Perspect. 2007 Apr;20(3):155-63. doi: 10.1358/dnp.2007.20.3.1092096. Drug News Perspect. 2007. PMID: 17520092 Review.
Targeting death-inducing receptors in cancer therapy.
Takeda K, Stagg J, Yagita H, Okumura K, Smyth MJ. Takeda K, et al. Among authors: stagg j. Oncogene. 2007 May 28;26(25):3745-57. doi: 10.1038/sj.onc.1210374. Oncogene. 2007. PMID: 17530027 Review.
From cancer immunosurveillance to cancer immunotherapy.
Stagg J, Johnstone RW, Smyth MJ. Stagg J, et al. Immunol Rev. 2007 Dec;220:82-101. doi: 10.1111/j.1600-065X.2007.00566.x. Immunol Rev. 2007. PMID: 17979841 Review.
Mesenchymal stem cells in cancer.
Stagg J. Stagg J. Stem Cell Rev. 2008 Summer;4(2):119-24. doi: 10.1007/s12015-008-9030-4. Epub 2008 May 21. Stem Cell Rev. 2008. PMID: 18493880 Review.
Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis.
Stagg J, Divisekera U, McLaughlin N, Sharkey J, Pommey S, Denoyer D, Dwyer KM, Smyth MJ. Stagg J, et al. Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1547-52. doi: 10.1073/pnas.0908801107. Epub 2010 Jan 4. Proc Natl Acad Sci U S A. 2010. PMID: 20080644 Free PMC article.
CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis.
Stagg J, Divisekera U, Duret H, Sparwasser T, Teng MW, Darcy PK, Smyth MJ. Stagg J, et al. Cancer Res. 2011 Apr 15;71(8):2892-900. doi: 10.1158/0008-5472.CAN-10-4246. Epub 2011 Feb 3. Cancer Res. 2011. PMID: 21292811
Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy.
Stagg J, Loi S, Divisekera U, Ngiow SF, Duret H, Yagita H, Teng MW, Smyth MJ. Stagg J, et al. Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):7142-7. doi: 10.1073/pnas.1016569108. Epub 2011 Apr 11. Proc Natl Acad Sci U S A. 2011. PMID: 21482773 Free PMC article.
116 results
Jump to page
Feedback